LICENSE AGREEMENTLicense Agreement • October 24th, 2018 • Apricus Biosciences, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (the “Agreement”) is dated as of September 21, 2016 (the “Effective Date”) by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Ligand”), Neurogen Corporation, a Delaware corporation (“Neurogen”) and CyDex Pharmaceuticals, Inc., a Delaware corporation (“CyDex”), and Seelos Therapeutics, Inc., a Delaware corporation (“Seelos”). It is understood that Neurogen and CyDex are wholly-owned subsidiaries of Ligand; that the technology being licensed hereunder toward Aplindore Licensed Products and H3 Receptor Licensed Products is owned or in-licensed by Neurogen (it being possible that some components of the Aplindore Program and/or the H3 Receptor Program are instead owned by Ligand) and that the technology being licensed hereunder toward CEA Licensed Products is owned or in-licensed by CyDex (it being possible that some components of the CEA Program are instead owned by Ligand). Ligand, Neurogen and CyDex are referred to collectively herein as “Li
CONVERSION AGREEMENTConversion Agreement • October 24th, 2018 • Apricus Biosciences, Inc. • Pharmaceutical preparations • New York
THIS CONVERSION AGREEMENT (this “Agreement”) is effective as of October 15, 2018 by and among SEELOS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the parties listed on the Schedule of Holders attached to this Agreement as EXHIBIT A (each, a “Holder” and, collectively, the “Holders”).
